Early Adverse Events predict Survival Outcomes in HER2-positive Advanced Breast Cancer Patients treated with Lapatinib plus Capecitabine

Background: This study aimed to investigate the impact of early adverse events (AE) following the initiation of lapatinib plus capecitabine on the progression-free survival (PFS) and overall survival (OS) outcomes of human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer (AB...

Descripción completa

Detalles Bibliográficos
Autores principales: Ang, Fang L.I., Rowland, Andrew, Modi, Natansh D., McKinnon, Ross A., Sorich, Michael J., Hopkins, Ashley M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097941/
https://www.ncbi.nlm.nih.gov/pubmed/32231738
http://dx.doi.org/10.7150/jca.41996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097941/
https://www.ncbi.nlm.nih.gov/pubmed/32231738
http://dx.doi.org/10.7150/jca.41996

Ejemplares similares